{"nctId":"NCT00621140","briefTitle":"Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control","startDateStruct":{"date":"2008-02"},"conditions":["Diabetes Mellitus, Type 2"],"count":503,"armGroups":[{"label":"linagliptin 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: linagliptin"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"linagliptin","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Male or female patients with type 2 diabetes and insufficient glycaemic control.\n* Age 18 or over and not older than 80 years\n\nExclusion criteria:\n\n* Use of more than one oral antidiabetic agent within 10 weeks prior to informed consent, insulin, glitazones or GLP-1 analogues within 3 months.\n* Myocardial infarction, stroke or transient ischaemic attack within 6 months prior to informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline at Week 24","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.07"},{"groupId":"OG001","value":"-0.44","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 6","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.05"},{"groupId":"OG001","value":"-0.37","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 12","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.06"},{"groupId":"OG001","value":"-0.46","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 18","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.07"},{"groupId":"OG001","value":"-0.45","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 24","description":"This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.84","spread":"2.98"},{"groupId":"OG001","value":"-8.47","spread":"2.03"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 6","description":"This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.73","spread":"2.33"},{"groupId":"OG001","value":"-10.87","spread":"1.59"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 12","description":"This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.23","spread":"2.63"},{"groupId":"OG001","value":"-10.75","spread":"1.80"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 18","description":"This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.11","spread":"2.82"},{"groupId":"OG001","value":"-7.25","spread":"1.93"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7.0% at Week 24","description":"The percentage of patients with an HbA1c value below 7.0% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c \\>= 7.0%. Only patients with baseline HbA1c \\>= 7%","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"0"},{"groupId":"OG001","value":"25.2","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c<7.0% at Week 24","description":"The percentage of patients with an HbA1c value below 7.0% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c \\>= 7.0%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"28.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <6.5% at Week 24","description":"The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c \\>= 6.5%. Only patients with baseline HbA1c \\>= 6.5%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"0"},{"groupId":"OG001","value":"10.6","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c<6.5% at Week 24","description":"The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c \\>= 6.5%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"10.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c Lowering by 0.5% at Week 24","description":"The percentage of patients with an HbA1c reduction from baseline \\>= 0.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":"0"},{"groupId":"OG001","value":"47.1","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Adjusted Means for 2h Post Prandial Blood Glucose (PPG) Change From Baseline at Week 24","description":"This change from baseline reflects the Week 24 2h PPG minus the baseline 2h PPG. Means are treatment adjusted for baseline HbA1c, baseline PPG and previous anti-diabetic medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.87","spread":"10.33"},{"groupId":"OG001","value":"-33.51","spread":"6.19"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":167},"commonTop":["Hyperglycaemia"]}}}